New hope for hepatitis c patients who relapsed: 12-week drug combo shows promise
NCT ID NCT07565948
First seen May 10, 2026 · Last updated May 10, 2026
Summary
This study tests a 12-week course of three antiviral drugs (sofosbuvir, velpatasvir, voxilaprevir) in 200 adults with chronic hepatitis C whose infection returned after earlier treatment. The main goal is to see if the virus becomes undetectable 12 weeks after finishing the drugs. Researchers also track liver function and side effects. This is a salvage therapy option for hard-to-treat cases.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS C VIRUS (HCV) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Xiangya Hospital of Central South University
Changsha, Hunan, 410000, China
Conditions
Explore the condition pages connected to this study.